跳至主要内容
临床试验/NCT01523106
NCT01523106撤回不适用

L-carnitine to Treat Fatigue Associated With Crohn's Disease

University of California, San Francisco1 个研究点 分布在 1 个国家开始时间: 2013年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Change in fatigue severity scale

研究概览

简要总结

This is a randomized, double-blind, placebo-controlled study, comparing the effect of L-carnitine vs placebo on fatigue among Crohn's disease patients.

The specific aim of this study is to determine if treatment with L-carnitine is more effective than placebo at decreasing fatigue severity scores, while accounting for disease activity and concomitant anemia, depression/anxiety and poor sleep quality.

详细描述

A total of 100 patients will be recruited, in order to be able ensure to detect a significant difference in fatigue between the treatment and control groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients will have had previously macro- and microscopically verified Crohn's disease, as defined by traditional clinical and endoscopic standards.
  • To be included, patients need to have disease which is either in remission or is mild to moderate in severity, as defined by the Harvey-Bradshaw Index Score (HBI<16).
  • In addition, patients will need to answer "yes" to the screening study entry question ("Is fatigue a signficant problem for you currently?").

排除标准

  • Exclusion criteria will include:
  • age <18 or >70 years
  • pregnancy or delivery within 6 months
  • malignancy diagnosed within 1 year
  • oral/intravenous steroid treatment within 6 months
  • any surgery within 6 months
  • presence of a stoma or ileo-anal J-pouch anastomosis
  • concurrent hepatitis B or C infection
  • cirrhosis
  • renal insufficiency (CrCl<60) and history of seizure disorder or hypothyrodism.
  • prior to study enrollment
  • women of child-bearing age will need to undergo pregnancy testing.

研究组 & 干预措施

Carnitine

Active Comparator

Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months

干预措施: L-carnitine (Drug)

Placebo

Placebo Comparator

Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.

干预措施: Placebo (Other)

结局指标

主要结局

Change in fatigue severity scale

时间窗: From baseline to 3 months after intervention initiation

The Fatigue Severity Score is a validated instrument to assess fatigue associated with chronic disease. The scale ranges from scores from 9 to 63, with a higher score indicated greater fatigue.

次要结局

  • Change in Multidimensional Fatigue Inventory(From baseline to 3 months after intevention initiation)
  • Change in handgrip strength(From baseline to 3 months after treatment intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验